Fluoroquinolone antibiotics: properties of the class and individual agents
- PMID: 1638577
Fluoroquinolone antibiotics: properties of the class and individual agents
Abstract
The broad spectrum of activity and bactericidal nature of the fluoroquinolones, together with their excellent absorption, rapid distribution, and high tissue concentration, make them excellent therapeutic agents for the management of a number of complicated community-acquired and nosocomial infections of the urinary tract, bone and soft tissue, gastrointestinal tract, and prostate, as well as some respiratory tract infections and sexually transmitted diseases. Data are presented and reviewed concerning the in vitro activity, pharmacology, and clinical use of ciprofloxacin, norfloxacin, and ofloxacin, which have been available for some time, and lomefloxacin and temafloxacin, which are recently approved agents. The comparable qualities and differences in activity and clinical applications of these agents are considered. For many infections in selected patients, quinolones are excellent substitutes for parenteral agents. In general, adverse effects have been infrequent and rarely require drug discontinuation. Significant interactions, such as with theophylline and caffeine, have occurred but are quinolone dependent. Antacids can markedly impair the absorption of all quinolones. Because emerging resistance to Pseudomonas and Staphylococcus species have been observed, the improper use of the quinolones must be avoided, and the clinician must be aware that an unfavorable response may signal resistance. The development of future agents with better gram-positive activity, improved gram-negative coverage, and activity against unusual pathogens such as Chlamydia species and Mycobacterium species, will make these oral agents invaluable. Assessing the usefulness and safety of these antibiotics in children is an ongoing challenge.
Similar articles
-
Lomefloxacin and temafloxacin: two new fluoroquinolone antimicrobials.Clin Pharm. 1992 Sep;11(9):753-66. Clin Pharm. 1992. PMID: 1325892 Review.
-
The role of the fluoroquinolones.Pharmacotherapy. 1992;12(6 Pt 2):71S-85S. Pharmacotherapy. 1992. PMID: 1480503 Review.
-
The place of quinolones in bacterial infections.Adv Intern Med. 1991;36:1-32. Adv Intern Med. 1991. PMID: 2024577 Review.
-
Enoxacin: a new fluoroquinolone.Clin Pharm. 1989 Feb;8(2):97-107. Clin Pharm. 1989. PMID: 2645085 Review.
-
Overview of the fluoroquinolone antibiotics.Pharmacotherapy. 1993 Mar-Apr;13(2 Pt 2):4S-17S. Pharmacotherapy. 1993. PMID: 8386356 Review.
Cited by
-
Single-dose pharmacokinetics of oral fleroxacin in bacteremic patients.Antimicrob Agents Chemother. 1994 Jun;38(6):1219-24. doi: 10.1128/AAC.38.6.1219. Antimicrob Agents Chemother. 1994. PMID: 8092817 Free PMC article.
-
Current issues in the management of urinary tract infections: extended-release ciprofloxacin as a novel treatment option.Drugs. 2004;64(6):611-28. doi: 10.2165/00003495-200464060-00004. Drugs. 2004. PMID: 15018591 Review.
-
Urinary tract infections in adult general practice patients.Br J Gen Pract. 2002 Sep;52(482):752-61. Br J Gen Pract. 2002. PMID: 12236281 Free PMC article. Review.
-
Results of a randomized trial comparing sequential intravenous/oral treatment with ciprofloxacin plus metronidazole to imipenem/cilastatin for intra-abdominal infections. The Intra-Abdominal Infection Study Group.Ann Surg. 1996 Mar;223(3):303-15. doi: 10.1097/00000658-199603000-00012. Ann Surg. 1996. PMID: 8604912 Free PMC article. Clinical Trial.
-
Magnetically stimulated ciprofloxacin release from polymeric microspheres entrapping iron oxide nanoparticles.Int J Nanomedicine. 2015 Jul 9;10:4447-58. doi: 10.2147/IJN.S82830. eCollection 2015. Int J Nanomedicine. 2015. PMID: 26185446 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources